- Home
- OPBK vs URGN Comparison
OPBK vs URGN Comparison
Compare OPBK & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPBK
- URGN
- Stock Information
- Founded
- OPBK 2005
- URGN 2004
- Country
- OPBK United States
- URGN United States
- Employees
- OPBK N/A
- URGN N/A
- Industry
- OPBK Major Banks
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- OPBK Finance
- URGN Health Care
- Exchange
- OPBK Nasdaq
- URGN Nasdaq
- Market Cap
- OPBK 176.4M
- URGN 181.2M
- IPO Year
- OPBK 2018
- URGN 2017
- Fundamental
- Price
- OPBK $14.12
- URGN $12.95
- Analyst Decision
- OPBK Hold
- URGN Strong Buy
- Analyst Count
- OPBK 1
- URGN 8
- Target Price
- OPBK $18.00
- URGN $23.00
- AVG Volume (30 Days)
- OPBK 160.0K
- URGN 5.5M
- Earning Date
- OPBK 07-24-2025
- URGN 08-12-2025
- Dividend Yield
- OPBK 3.40%
- URGN N/A
- EPS Growth
- OPBK 0.92
- URGN N/A
- EPS
- OPBK 1.42
- URGN N/A
- Revenue
- OPBK $81,356,000.00
- URGN $91,871,000.00
- Revenue This Year
- OPBK $19.87
- URGN $36.65
- Revenue Next Year
- OPBK $10.60
- URGN $88.35
- P/E Ratio
- OPBK $9.95
- URGN N/A
- Revenue Growth
- OPBK 4.15
- URGN 8.98
- 52 Week Low
- OPBK $9.43
- URGN $3.42
- 52 Week High
- OPBK $18.57
- URGN $18.15
- Technical
- Relative Strength Index (RSI)
- OPBK 72.94
- URGN 63.17
- Support Level
- OPBK $11.52
- URGN $12.73
- Resistance Level
- OPBK $11.94
- URGN $13.93
- Average True Range (ATR)
- OPBK 0.44
- URGN 1.24
- MACD
- OPBK 0.25
- URGN -0.00
- Stochastic Oscillator
- OPBK 86.67
- URGN 50.49
About OPBK OP Bancorp
OP Bancorp is engaged in the general commercial banking business in Los Angeles, Orange, and Santa Clara Counties, California, Carrollton, Texas, and Las Vegas, Nevada. The Bank is focused on serving the banking needs of small- and medium-sized businesses, professionals, and residents with a particular emphasis on Korean and other ethnic minority communities. It operates with eleven full branches.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.